1. Home
  2. FOFO vs NEUP Comparison

FOFO vs NEUP Comparison

Compare FOFO & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

FOFO

Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

N/A

Current Price

$2.15

Market Cap

19.2M

Sector

N/A

ML Signal

N/A

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$3.74

Market Cap

20.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FOFO
NEUP
Founded
2017
1996
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
19.2M
20.6M
IPO Year
2025
2002

Fundamental Metrics

Financial Performance
Metric
FOFO
NEUP
Price
$2.15
$3.74
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
5.2K
47.0K
Earning Date
03-13-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.09
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.75
$3.19
52 Week High
$68.00
$21.31

Technical Indicators

Market Signals
Indicator
FOFO
NEUP
Relative Strength Index (RSI) 38.84 45.39
Support Level $1.79 $3.70
Resistance Level $2.70 $4.15
Average True Range (ATR) 0.15 0.14
MACD -0.02 -0.01
Stochastic Oscillator 6.38 9.52

Price Performance

Historical Comparison
FOFO
NEUP

About FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: